|
MOther-Child Interaction Assessment TRAINING for Pediatricians
RECRUITINGN/ASponsored by University Hospital, Lille
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital, Lille
Started2017-12-02
Est. completion2026-12
Eligibility
Age23 Days – 37 Days
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT03300713
Summary
The originality of the MOCITRAINING study lies in the integration of infant and maternal care during the pediatric consultation and the assessment of the impact of this type of care in the short and medium term on The MOCITRAINING program could contribute to improving the quality of parent-child interactions.
Eligibility
Age: 23 Days – 37 DaysHealthy volunteers accepted
Inclusion Criteria: * Each child will be included WITH his biological mother at the first-month visit after birth. * Age: 1 month + / - 15 days (child), accompanied by his biological mother * Mother able to read French; * Signed consent letter after complete information of parents about the MOCITRAINING study, its principle, advantages and disadvantages. Exclusion Criteria: * Preterm babies. * Children from a twin or multiple pregnancy. * Children with somatic diagnosis explaining the presence of digestive, sleeping or interactional disorders. * Refusal to participate after clear information about the study; * Refusal to sign the consent letter; * Refusal to be informed of a diagnostic hypothesis; * Participants not covered by the Social Security system; * Participants incapable of consenting or under legal protection (guardianship or curatorship).
Conditions4
Child Behavior DisordersDepressionDepression, PostpartumMother-Child Relations
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital, Lille
Started2017-12-02
Est. completion2026-12
Eligibility
Age23 Days – 37 Days
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT03300713